Citigroup Forecasts Strong Price Appreciation for Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health (NYSE:HIMS) had its target price boosted by Citigroup from $25.00 to $27.00 in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a sell rating on the stock.

HIMS has been the topic of several other reports. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their price objective for the company from $42.00 to $60.00 in a report on Tuesday, February 18th. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Bank of America upped their price objective on shares of Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a report on Thursday, February 20th. BTIG Research initiated coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Needham & Company LLC upped their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and an average price target of $33.40.

Hims & Hers Health Trading Down 22.1 %

NYSE HIMS opened at $39.95 on Tuesday. The firm’s fifty day moving average price is $35.62 and its two-hundred day moving average price is $26.25. Hims & Hers Health has a 1 year low of $9.67 and a 1 year high of $72.98. The firm has a market capitalization of $8.73 billion, a P/E ratio of 90.79 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. On average, research analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Andrew Dudum sold 33,513 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $1,118,296.76. This represents a 50.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 268,932 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the completion of the transaction, the insider now directly owns 169,803 shares of the company’s stock, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,097,578 shares of company stock valued at $38,080,320 over the last quarter. 17.71% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Main Management ETF Advisors LLC bought a new position in shares of Hims & Hers Health in the third quarter worth about $672,000. Robeco Institutional Asset Management B.V. bought a new position in shares of Hims & Hers Health in the third quarter worth about $604,000. Royce & Associates LP lifted its holdings in shares of Hims & Hers Health by 17.0% in the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock worth $6,281,000 after acquiring an additional 49,500 shares during the last quarter. Versor Investments LP bought a new position in shares of Hims & Hers Health in the third quarter worth about $634,000. Finally, International Assets Investment Management LLC bought a new position in Hims & Hers Health in the 3rd quarter valued at approximately $6,790,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.